Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”

Sandoz has decided to discontinue development of its generic version of GlaxoSmithKline’s Advair Diskus respiratory brand, resulting in an impairment charge of $442m.

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.